These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 33269716)

  • 1. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
    Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
    Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle invasive bladder cancer: where is the field headed?
    Ghatalia P; Kaur J; Sonpavde G
    Expert Opin Biol Ther; 2023; 23(9):913-927. PubMed ID: 37477127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative chemotherapy for muscle invasive bladder cancer.
    Rudzinski JK; Basappa NS; North S
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):249-54. PubMed ID: 26125306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK; Ruel NH; Wilson TG; Yuh BE
    Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y; Kim YS; Hong B; Cho YM; Lee JL
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
    J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
    Kartolo A; Kassouf W; Vera-Badillo FE
    Eur Urol; 2021 Dec; 80(6):679-681. PubMed ID: 34366212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Lu L; Chen C; Cheng H; Ding H; Tian J; Wang H; Wang Z
    BMC Cancer; 2023 Nov; 23(1):1066. PubMed ID: 37932689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
    Zargar-Shoshtari K; Zargar H; Dinney CP; Ercole CE; Sharma P; Kovac E; Grivas PD; Stephenson AJ; Shah JB; Black PC; Spiess PE
    World J Urol; 2016 May; 34(5):695-701. PubMed ID: 26286880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.